IMMUNITYBIO, INC. (IBRX) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 165.79M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 1.09M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $165.79M | $1.09M | (m) |
| 2026-03-31 | (m) | $140.98M | $933.00K | (m) |
| 2025-12-31 | (m) | $113.29M | $753.00K | (m) |
| 2025-09-30 | (m) | $82.56M | $371.00K | (m) |
| 2025-06-30 | (m) | $56.60M | $194.00K | (m) |
| 2025-03-31 | (m) | $31.22M | $58.00K | (m) |
| 2024-12-31 | (m) | $14.74M | $0.00 | (m) |
| 2024-09-30 | (m) | $7.33M | (m) | (m) |
| 2024-06-30 | (m) | $1.31M | (m) | (m) |
| 2024-03-31 | (m) | $302.00K | (m) | (m) |
| 2023-12-31 | (m) | $622.00K | (m) | (m) |
| 2023-09-30 | (m) | $556.00K | (m) | (m) |
| 2023-06-30 | (m) | $592.00K | (m) | (m) |
| 2023-03-31 | (m) | $586.00K | (m) | (m) |
| 2022-12-31 | (m) | $240.00K | (m) | (m) |
| 2022-09-30 | (m) | $557.00K | (m) | (m) |
| 2022-06-30 | (m) | $505.00K | (m) | (m) |
| 2022-03-31 | (m) | $809.00K | (m) | (m) |
| 2021-12-31 | (m) | $934.00K | (m) | (m) |
| 2021-09-30 | (m) | $397.00K | (m) | (m) |
| 2021-06-30 | (m) | $482.00K | (m) | (m) |
| 2021-03-31 | (m) | $579.00K | (m) | (m) |
| 2020-12-31 | (m) | $111.00K | (m) | (m) |
| 2020-09-30 | (m) | $99.00K | (m) | (m) |
| 2020-06-30 | (m) | $43.00K | (m) | (m) |
| 2020-03-31 | (m) | $59.00K | (m) | (m) |
| 2019-12-31 | (m) | $43.00K | (m) | (m) |
| 2019-09-30 | (m) | $41.00K | (m) | (m) |
| 2019-06-30 | (m) | $60.00K | (m) | (m) |
| 2019-03-31 | (m) | $47.00K | (m) | (m) |
| 2018-12-31 | (m) | $47.00K | (m) | (m) |
| 2018-09-30 | (m) | $52.00K | (m) | (m) |
| 2018-06-30 | (m) | $29.00K | (m) | (m) |
| 2018-03-31 | (m) | $39.00K | (m) | (m) |
| 2017-12-31 | (m) | $45.00K | (m) | (m) |
| 2017-09-30 | (m) | $47.00K | (m) | (m) |
| 2017-06-30 | (m) | $51.00K | (m) | (m) |
| 2017-03-31 | (m) | $49.00K | (m) | (m) |
| 2016-12-31 | (m) | $44.00K | (m) | (m) |
| 2016-09-30 | (m) | $44.00K | (m) | (m) |
| 2016-06-30 | (m) | $43.00K | (m) | (m) |
| 2016-03-31 | (m) | $122.00K | (m) | (m) |
| 2015-12-31 | (m) | $236.00K | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $475.00K | (m) | (m) |
| 2014-12-31 | (m) | $641.00K | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $600.00K | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |